Zhengye Biotechnology Holding Limited income statement ZYBT

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Zhengye Biotechnology Holding Limited reported revenue of $16.6 million, down 34.8% from the year before. It recorded a net loss of $10.0 million. The operating loss came to $10.1 million, an operating margin of -60.6%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
17
-34.8%
26
Cost of revenue
13
+1.6%
13
Gross profit
3
-72.7%
13
Research and development
3
+46.9%
2
Selling, general and administrative
11
+22.5%
9
Operating income
-10
-547.8%
2
Interest income
0
-56.2%
0
Other non-operating income (expense)
-0
—
Other income (expense)
-0
+29.7%
-0
Pretax income
-10
-621.0%
2
Income tax
2
+1149.6%
0
Net income
-10
-744.0%
2
Basic EPS
—
0.03
Diluted EPS
—
0.03
Weighted average shares, basic
47
+3.7%
46
Weighted average shares, diluted
47
+3.7%
46
Other measures
Depreciation and amortization
4
+11.8%
3
EBITDA
-6
-214.7%
6
Interest coverage
-20.75x
4.06x
Margins
Gross margin
20.51%
48.99%
Operating margin
-60.60%
8.82%
Pretax margin
-61.78%
7.73%
Profit margin
-59.99%
6.07%
EBITDA margin
-38.36%
21.79%
Effective tax rate
—
6.44%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ZYBT (Nasdaq)
Incorporated in
China
Headquarters
Jilin
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1975641

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.